WHAT THE STUDIES FOUND
Early CJC-1295 studies found growth hormone raised for days.
The compound has thirty small protein parts; four differ. Half remains after ~30 minutes without DAC, and ~7-8 days with DAC.
What did studies find about CJC-1295?
Blood tests changed for several days. The study didn't test how people felt.
Healthy adults joined a phase-1 study, an early safety test [1]. After one shot, their growth hormone rose twofold to tenfold.
After at least six days, growth hormone was still high. Insulin-like growth factor 1 rose 1.5- to 3-fold [1].
That second hormone stayed up for nine to eleven days. It shows you how the body answered growth hormone.
CJC-1295 copies the hormone message that starts the growth gland. The message tells the gland when to act.
CJC-1295 has thirty protein parts, with four changed. DAC is a link added to the longer form.
The link joins a blood protein. The body's own message leaves in seven to twenty minutes [2][10].
Without DAC, half leaves in roughly thirty minutes. With DAC, blood tests find CJC-1295 for days; it isn't FDA-approved [13].
How does CJC-1295 change the blood tests?
Researchers followed two blood tests. Both rose after the compound reached the growth gland.
CJC-1295 reaches a receptor, a docking place on the gland [1]. Once docked, it makes the gland release stored growth hormone.
The body's own message uses that receptor too [1]. DAC keeps the man-made message in blood much longer.
Growth hormone still came in bursts. The number of bursts didn't change [2].
Each burst rose higher above its low point. The gland kept answering during the study.
Researchers also checked insulin-like growth factor 1, a hormone made by the liver. They only watched people during the study.
Insulin-like growth factor 1 rose, then fell as the compound left the blood. The change says nothing about how you felt.
Read how CJC-1295 works for each study step. You'll also see what the tests can't prove.
What did researchers measure with CJC-1295?
The CJC-1295 papers measured blood changes. They didn't test whether people felt better.
A 2006 phase-1 safety study gave healthy adults one shot. Amounts were 30, 60, 125, or 250 micrograms based on each kilogram the person weighed [1].
Another 2006 study ran for 49 days [16]. It used 60 micrograms per kilogram, with shots weekly or every other week.
IGF-1, a liver-made hormone, built up during that time. A linked 2006 paper counted each growth-hormone burst [2].
Researchers measured each burst's height and its low point. Both rose, while the number of bursts stayed the same.
One 2006 study was in mice [3]. Those mice lacked the usual hormone message that starts the gland.
Daily CJC-1295 restored their weight, tissue apart from fat, and fat under the skin. A 2009 study gave one 90 microgram amount for each kilogram [4].
IGF-1 and several other blood proteins changed. For you, those changes don't show that health improved.
How do the two forms differ?
The DAC link changes how long the compound stays in blood. The main compound stays the same.
CJC-1295 with DAC has a link at one end [5]. That link attaches the compound to albumin.
This blood protein slows the compound's exit. In healthy adults, half remained after about 5.8 to 8.1 days [1].
That time is the half-life. It shows you when the blood amount is half.
CJC-1295 without DAC has the same thirty parts. The same four parts are changed.
Researchers call it modified GRF. Without DAC, half remains after about 30 minutes.
The study lists changed parts by place: 2, 8, 15, and 27 [6]. Those changes keep the body from cutting between parts 2 and 3.
Only DAC keeps the compound present for days. Compare both forms at CJC-1295 with DAC vs no DAC.
Why do studies pair CJC-1295 with ipamorelin?
The two compounds dock at different places. Either one can prompt a growth-hormone release.
CJC-1295 uses the docking place for the body's own message [7]. Ipamorelin uses another docking place.
Both sit on the same kind of gland cell. Each starts different steps inside that cell [8].
The two compounds don't push each other aside. With both present, some studies found a larger growth-hormone burst [8].
In some animal tests, the combined rise exceeded the two separate rises added together. That doesn't tell you what the pair does in people.
Studies also checked other gland hormones. Ipamorelin raised growth hormone without a clear rise in cortisol or the other hormones checked [15].
That finding explains why researchers chose the pair. It doesn't show that the pair helped anyone feel better.
The CJC-1295 studies measured hormone release, not relief. Read CJC-1295 and ipamorelin pairing for details.
What do FDA and sports rules say?
A research paper isn't permission to use a drug. FDA approval and sports rules matter here.
CJC-1295 isn't FDA-approved for any use [13]. In September 2023, FDA put it in Category 2 on a temporary pharmacy list called 503A.
Category 2 meant FDA saw major safety worries. In September 2024, the name left that group [13].
The person who proposed the drug had withdrawn the request. Leaving Category 2 wasn't a safety clearance.
The drug still has no active U.S. approval. A pharmacy has no current federal path to make it specially for one person.
The World Anti-Doping Agency also names CJC-1295 in Section S2.2 [12]. That section bans drugs that make growth hormone rise.
Covered athletes can't use the drug during or between events. The CJC-1295 side effects page covers trial reports.
The frequently asked questions give shorter answers. Each one lets you check the phase-1 human work.